Neoadjuvant chemotherapy for stage II–III breast cancer: a single-center experience

[1] Mathew J(2009)Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions Eur J Surg Oncol 35 113-22

[2] Asgeirsson KS(2011)Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods Eur J Surg Oncol 37 1038-43

[3] Cheung KL(2006)Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27 J Clin Oncol 24 2019-27

[4] Chan S(2001)A body image scale for use with cancer patients Eur J Cancer 37 189-97

[5] Dahda A(1996)The sexual activity questionnaire: A measure of women’s sexual functioning Qual Life Res 5 81-90

[6] Robertson JFR(2018)Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Lancet Oncol 19 27-39

[7] Espinosa-Bravo M(2011)Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer Ann Surg Oncol. 18 2851-7

[8] Sao Avilés A(2005)Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res Off J Am Assoc Cancer Res. 11 5678-85

[9] Esgueva A(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet Lond Engl. 384 164-72

[10] Córdoba O(2018)Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy Breast Cancer Res Treat. 170 559-67

[1] Mathew J(2009)Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions Eur J Surg Oncol 35 113-22

[2] Asgeirsson KS(2011)Breast conservative surgery after neoadjuvant chemotherapy in breast cancer patients: comparison of two tumor localization methods Eur J Surg Oncol 37 1038-43

[3] Cheung KL(2006)Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27 J Clin Oncol 24 2019-27

[4] Chan S(2001)A body image scale for use with cancer patients Eur J Cancer 37 189-97

[5] Dahda A(1996)The sexual activity questionnaire: A measure of women’s sexual functioning Qual Life Res 5 81-90

[6] Robertson JFR(2018)Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials Lancet Oncol 19 27-39

[7] Espinosa-Bravo M(2011)Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer Ann Surg Oncol. 18 2851-7

[8] Sao Avilés A(2005)Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res Off J Am Assoc Cancer Res. 11 5678-85

[9] Esgueva A(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet Lond Engl. 384 164-72

[10] Córdoba O(2018)Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy Breast Cancer Res Treat. 170 559-67